ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
1
World Health Organization, 1992. The control of schistosomiasis: report of the expert committee. World Health Organ Tech Rep Ser 830 :1–86.
-
2
Saathoff E, Olsen A, Magnussen P, Kvalsvig JD, Becker W, Appleton CC, 2004. Patterns of Schistosoma haematobium infection, impact of praziquantel treatment and re-infection after treatment in a cohort of schoolchildren from rural KwaZulu-Natal/South Africa. BMC Infect Dis 4 :40.
-
3
Gryseels B, Nkunliyinka L, Coosemans H, 1987. Field trials of praziquantel and amniquina for the treatment of schistosomiasis mansoni in Burundi. Trans R Soc Trop Med Hyg 81 :641– 644.
-
4
Whitty CJM, Mabey DC, Armstrong M, Wright SG, Chiodini PL, 2000. Presentation and outcome of 1107 cases of schistosomiasis from Africa diagnosed in a non-endemic country. Trans R Soc Trop Med Hyg 94 :531–534.
-
5
Ismail M, Metwally A, Farghaly A, Bruce J, Tao LF, Bennett JL, 1996. Characterization of isolates of Schistosoma mansoni from Egyptian villagers that tolerate high doses of praziquantel. Am J Trop Med Hyg 55 :214–218.
-
6
Van Lieshout L, Stelma FF, Guisse F, Falcao ST, Ferreira ST, Polman K, van Dam GJ, Diakhate M, Sow S, Deelder A, Gryseels B, 1999. The contribution of host-related factors to low cure rates of praziquantel for the treatment of Schistosoma mansoni in Senegal. Am J Trop Med Hyg 61 :760–765.
-
7
Picquet M, Vercruysse J, Shaw DJ, Diop M, Ly A, 1998. Efficacy of praziquantel against Schistosoma mansoni in northern Senegal. Trans R Soc Trop Med Hyg 92 :90–93.
-
8
Lawn S, Lucas S, Chiodini P, 2003. Schistosoma mansoni infection: failure of standard treatment with praziquantel in a returned traveller. Trans R Soc Trop Med Hyg 97 :100–101.
-
9
Corachán M, Ruiz L, Valls ME, Gascón J, 1992. Schistosomiasis and the Dogon country (Mali). Am J Trop Med Hyg 47 :6–9.
-
10
Doumenge JP, Mott KE, Cheung C, Villenave D, Chapuis C, Perrin MF, Reaud-Thomas G, eds, 1987. Atlas of the Global Distribution of Schistosomiasis. Bordeaux, France: Presses Universitaires de Bordeaux, 75–80.
-
11
Ismail M, Metwally A, Farghaly A, Bruce J, Tao LF, Bennett JL, 1999. Resistance to praziquantel: direct evidence from Schistosoma mansoni isolated from Egyptian villagers. Am J Trop Med Hyg 60 :932–935.
-
12
King CH, Muchiri EM, Ouma JH, 2000. Evidence against rapid emergence of praziquantel resistance in Schistosoma haematobium, Kenya. Emerg Infect Dis 6 :585–594.
-
13
Kumar V, Gryseels B, 1994. Use of Praziquantel against schistosomiasis: a review of the current status. Int J Antimicrob Agents 4 :313–320.
-
14
Mourao SC, Costa PI, Salgado HR, Gremiao MP, 2005. Improvement of antischistosomal activity of praziquantel by incorporation into phosphatidylcholine-containing liposomes. Int J Pharm 295 :157–162.
-
15
Ismail M, Botros S, Metwally A, William S, Farghally A, Tao LF, Day TA, Bennett JL, 1999. Resistance to praziquantel: direct evidence from Schistosoma mansoni isolated from Egyptian villagers. Am J Trop Med Hyg 60 :932–935.
-
16
Schwartz E, Pick N, Shazberg G, Potasman I, 2002. Hematospermia due to schistosome infection in travellers: diagnostic and treatment challenges. J Infect Dis 35 :1420–1424.
-
17
Corachan M, Valls ME, Almeda J, Vilana R, Gascón J, 1994. Hematospermia: a new etiology of clinical interest. Am J Trop Med Hyg 50 :580–584.
| Past two years | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 247 | 202 | 24 |
| Full Text Views | 419 | 3 | 1 |
| PDF Downloads | 148 | 3 | 1 |
FAILURE OF STANDARD TREATMENT WITH PRAZIQUANTEL IN TWO RETURNED TRAVELERS WITH SCHISTOSOMA HAEMATOBIUM INFECTION
DAVID ALONSO
DAVID ALONSO
International Health Center, e Servicio de Microbiología Centro de Diagnóstico Biomédico Clínic, Institut d’Investigacions Biomediques August Pi i Sunyer, Hospital Clinic, Barcelona, Spain
Search for other papers by DAVID ALONSO in
Current site
Google Scholar
PubMed
Search for other papers by DAVID ALONSO in
Current site
Google Scholar
PubMed
JOSE MUÑOZ
JOSE MUÑOZ
International Health Center, e Servicio de Microbiología Centro de Diagnóstico Biomédico Clínic, Institut d’Investigacions Biomediques August Pi i Sunyer, Hospital Clinic, Barcelona, Spain
Search for other papers by JOSE MUÑOZ in
Current site
Google Scholar
PubMed
Search for other papers by JOSE MUÑOZ in
Current site
Google Scholar
PubMed
JOAQUIM GASCÓN
JOAQUIM GASCÓN
International Health Center, e Servicio de Microbiología Centro de Diagnóstico Biomédico Clínic, Institut d’Investigacions Biomediques August Pi i Sunyer, Hospital Clinic, Barcelona, Spain
Search for other papers by JOAQUIM GASCÓN in
Current site
Google Scholar
PubMed
Search for other papers by JOAQUIM GASCÓN in
Current site
Google Scholar
PubMed
MARIA EUGENIA VALLS
MARIA EUGENIA VALLS
International Health Center, e Servicio de Microbiología Centro de Diagnóstico Biomédico Clínic, Institut d’Investigacions Biomediques August Pi i Sunyer, Hospital Clinic, Barcelona, Spain
Search for other papers by MARIA EUGENIA VALLS in
Current site
Google Scholar
PubMed
Search for other papers by MARIA EUGENIA VALLS in
Current site
Google Scholar
PubMed
MANUEL CORACHAN
MANUEL CORACHAN
International Health Center, e Servicio de Microbiología Centro de Diagnóstico Biomédico Clínic, Institut d’Investigacions Biomediques August Pi i Sunyer, Hospital Clinic, Barcelona, Spain
Search for other papers by MANUEL CORACHAN in
Current site
Google Scholar
PubMed
Search for other papers by MANUEL CORACHAN in
Current site
Google Scholar
PubMed
A single 40 mg/kg dose of praziquantel (PZQ) continues to be the standard treatment for schistosomiasis caused by S. mansoni and S. haematobium in all clinical settings. Experimental development of drug resistance and the recent isolation of S. mansoni strains with a natural tolerance to high doses of PZQ have raised concerns over the adequacy of such a dose. We describe two Spanish travelers with genitourinary schistosomiasis caused by S. haematobium in whom repeated standard treatment failed to clear the infection.
Author Notes
ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
1
World Health Organization, 1992. The control of schistosomiasis: report of the expert committee. World Health Organ Tech Rep Ser 830 :1–86.
-
2
Saathoff E, Olsen A, Magnussen P, Kvalsvig JD, Becker W, Appleton CC, 2004. Patterns of Schistosoma haematobium infection, impact of praziquantel treatment and re-infection after treatment in a cohort of schoolchildren from rural KwaZulu-Natal/South Africa. BMC Infect Dis 4 :40.
-
3
Gryseels B, Nkunliyinka L, Coosemans H, 1987. Field trials of praziquantel and amniquina for the treatment of schistosomiasis mansoni in Burundi. Trans R Soc Trop Med Hyg 81 :641– 644.
-
4
Whitty CJM, Mabey DC, Armstrong M, Wright SG, Chiodini PL, 2000. Presentation and outcome of 1107 cases of schistosomiasis from Africa diagnosed in a non-endemic country. Trans R Soc Trop Med Hyg 94 :531–534.
-
5
Ismail M, Metwally A, Farghaly A, Bruce J, Tao LF, Bennett JL, 1996. Characterization of isolates of Schistosoma mansoni from Egyptian villagers that tolerate high doses of praziquantel. Am J Trop Med Hyg 55 :214–218.
-
6
Van Lieshout L, Stelma FF, Guisse F, Falcao ST, Ferreira ST, Polman K, van Dam GJ, Diakhate M, Sow S, Deelder A, Gryseels B, 1999. The contribution of host-related factors to low cure rates of praziquantel for the treatment of Schistosoma mansoni in Senegal. Am J Trop Med Hyg 61 :760–765.
-
7
Picquet M, Vercruysse J, Shaw DJ, Diop M, Ly A, 1998. Efficacy of praziquantel against Schistosoma mansoni in northern Senegal. Trans R Soc Trop Med Hyg 92 :90–93.
-
8
Lawn S, Lucas S, Chiodini P, 2003. Schistosoma mansoni infection: failure of standard treatment with praziquantel in a returned traveller. Trans R Soc Trop Med Hyg 97 :100–101.
-
9
Corachán M, Ruiz L, Valls ME, Gascón J, 1992. Schistosomiasis and the Dogon country (Mali). Am J Trop Med Hyg 47 :6–9.
-
10
Doumenge JP, Mott KE, Cheung C, Villenave D, Chapuis C, Perrin MF, Reaud-Thomas G, eds, 1987. Atlas of the Global Distribution of Schistosomiasis. Bordeaux, France: Presses Universitaires de Bordeaux, 75–80.
-
11
Ismail M, Metwally A, Farghaly A, Bruce J, Tao LF, Bennett JL, 1999. Resistance to praziquantel: direct evidence from Schistosoma mansoni isolated from Egyptian villagers. Am J Trop Med Hyg 60 :932–935.
-
12
King CH, Muchiri EM, Ouma JH, 2000. Evidence against rapid emergence of praziquantel resistance in Schistosoma haematobium, Kenya. Emerg Infect Dis 6 :585–594.
-
13
Kumar V, Gryseels B, 1994. Use of Praziquantel against schistosomiasis: a review of the current status. Int J Antimicrob Agents 4 :313–320.
-
14
Mourao SC, Costa PI, Salgado HR, Gremiao MP, 2005. Improvement of antischistosomal activity of praziquantel by incorporation into phosphatidylcholine-containing liposomes. Int J Pharm 295 :157–162.
-
15
Ismail M, Botros S, Metwally A, William S, Farghally A, Tao LF, Day TA, Bennett JL, 1999. Resistance to praziquantel: direct evidence from Schistosoma mansoni isolated from Egyptian villagers. Am J Trop Med Hyg 60 :932–935.
-
16
Schwartz E, Pick N, Shazberg G, Potasman I, 2002. Hematospermia due to schistosome infection in travellers: diagnostic and treatment challenges. J Infect Dis 35 :1420–1424.
-
17
Corachan M, Valls ME, Almeda J, Vilana R, Gascón J, 1994. Hematospermia: a new etiology of clinical interest. Am J Trop Med Hyg 50 :580–584.
| Past two years | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 247 | 202 | 24 |
| Full Text Views | 419 | 3 | 1 |
| PDF Downloads | 148 | 3 | 1 |